On Monday, 23 March 2015, Nordic Nanovector was listed on the Main List at the Oslo Stock Exchange. Roy Hartvig Larsen, the founder of the Company and its patented technology, rang the bell.
Click here to see more pictures from the official listing venue on the stock exchange.
Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers.
The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.
Nordic Nanovector was established in 2009, leveraging expertise in targeted cancer therapy from the Norwegian Radium Hospital, and has its main office and laboratories in Oslo, Norway.